The impact of aprotinin on renal function after liver transplantation: An analysis of 1043 patients

American Journal of Transplantation

Volumn 7, Issue 10, 2007, Pages 2378-2387

  Warnaar, N ^a,b   Mallett, S V ^b   De Boer, M T ^a   Rolando, N ^b   Burroughs, A K ^b   Nijsten, M W N ^a   Slooff, M J H ^a   Rolles, K ^b   Porte, R J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antifibrinolytics; Aprotinin; Liver transplantation; Renal dysfunction; Renal function

Indexed keywords

APROTININ; CYCLOSPORIN; TACROLIMUS;

ADULT; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK; SCORING SYSTEM; SIDE EFFECT;

ADULT; APROTININ; CREATININE; FEMALE; FIBRINOLYSIS; HEMOSTATICS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34548303791     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01939.x     Document Type: Article

References (47)

1. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. Liver Transpl Surg 1997 3 : 655 659.
2. Bechstein WO, Neuhaus P. A surgeon's perspective on the management of coagulation disorders before liver transplantation. Liver Transpl Surg 1997 3 : 653.
3. Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989 47 : 978 984.
4. Porte RJ. Coagulation and fibrinolysis in orthotopic liver transplantation: Current views and insights. Semin Thromb Hemost 1993 19 : 191 196.
5. de Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ. Minimizing blood loss in liver transplantation: Progress through research and evolution of techniques. Dig Surg 2005 22 : 265 275.
6. Mannucci PM. Hemostatic drugs. N Engl J Med 1998 339 : 245 253.
7. Mallett SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990 336 : 886 887.
8. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989 2 : 924 925.
9. Molenaar IQ, Warnaar N, Groen H, Slooff MJ, Vergert ten E, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation; a systematic review and meta-analysis. Am J Transplant 2007 7 : 185 194.
10. Porte RJ, Molenaar IQ, Begliomini B et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. Lancet 2000 355 : 1303 1309.
11. Lemmer JH Jr., Stanford W, Bonney SL et al. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function. Ann Thorac Surg 1995 59 : 132 136.
12. Mangano DT, Tudor JC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 365.
13. Fischer JH, Knupfer P. High-dosage aprotinin (Trasylol) therapy-is it safe for the kidney? Langenbecks Arch Chir 1983 360 : 241 249.
14. Rustom R, Grime JS, Maltby P, Stockdale HR, Critchley M, Bone JM. Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man: Theoretical and practical considerations. Clin Sci (Lond) 1993 84 : 231 235.
15. Karkouti K, Beattie WS, Dattilo KM et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006 46 : 327 338.
16. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE-criteria, post-liver transplantation. Am J Transplant 2007 7 : 168 176.
17. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998 54 : 518 524.
18. Gonwa TA, Mai ML, Melton LB et al. Renal replacement therapy and orthotopic liver transplantation: The role of continuous veno-venous hemodialysis. Transplantation 2001 71 : 1424 1428.
19. Narayanan Menon KV, Nyberg SL, Harmsen WS et al. MELD and other factors associated with survival after liver transplantation. Am J Transplant 2004 4 : 819 825.
20. Cabezuelo JB, Ramirez P, Rios A et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006 69 : 1073 1080.
21. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004 8 : R204 R212.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
23. Molenaar IQ, Begliomini B, Grazi GL, Ringers J, Terpstra OT, Porte RJ. The effect of aprotinin on renal function in orthotopic liver transplantation. Transplantation 2001 71 : 247 252.
24. Perkins JD. Aprotinin: Effective, but risky? Liver Transpl 2006 12 : 1293 1294.
25. McBride WT, Allen S, Gormley SMC et al. Methylprednisolone favourably alters plasma and urinary cytokine homeostasis and subclinical renal injury at cardiac surgery. Cytokine 2004 27 : 81 89.
26. Kher A, Meldrum KK, Hile KL et al. Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. J Thorac Cardiovasc Surg 2005 130 : 662 669.
27. MacGilchrist A, Craig KJ, Hayes PC, Cumming AD. Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites. Clin Sci (Lond) 1994 87 : 329 335.
28. D'Ambra MN, Akins CW, Blackstone EH et al. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996 112 : 1081 1089.
29. Brown JR, Birkmeyer NJ, O'Çonnor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007 115 : 2801 2813.
30. Bridges CR. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation 2007 115 : 2790 2792.
31. Junge G, Schewior LV, Kohler S et al. Acute renal failure after liver transplantation: Incidence, etiology, therapy, and outcome. Transplant Proc 2006 38 : 723 724.
32. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, Curiel Balsera E, Fernandez Ortega JF, Quesada Garcia G. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004 10 : 1379 1385.
33. McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron 1990 55 : 121 128.
34. Velidedeoglu E, Bloom RD, Crawford MD et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004 77 : 553 556.
35. Bilbao I, Charco R, Balsells J et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998 12 : 123 129.
36. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003 9 : 741 747.
37. Sanchez EQ, Gonwa TA, Levy MF et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004 78 : 1048 1054.
38. Ishitani M, Wilkowski M, Stevenson W, Pruett T. Outcome of patients requiring hemodialysis after liver transplantation. Transplant Proc 1993 25 : 1762.
39. Contreras G, Garces G, Quartin AA et al. An epidemiologic study of early renal replacement therapy after orthotopic liver transplantation. J Am Soc Nephrol 2002 13 : 228 233.
40. Mangano DT, Miao Y, Vuylsteke A et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 479.
41. Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006 354 : 413 415.
42. Ferguson TB. Aprotinin - are these lessons learned? JAMA 2007 297 : 527 529.
43. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 2281.
44. Luellen JK, Shadish WR, Clark MH. Propensity scores: An introduction and experimental test. Eval Rev 2005 29 : 530 558.
45. Milroy SJ, Cottam S, Tan KC, Hilmi I, Oyesola B. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth 1995 75 : 747 751.
46. Molenaar IQ, Begliomini B, Martinelli G, Putter H, Terpstra OT, Porte RJ. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 2001 94 : 433 438.
47. Findlay JY, Kufner RP. Aprotinin reduces vasoactive medication use during adult liver transplantation. J Clin Anesth 2003 15 : 19 23.